Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
Aparna R. Parikh(Massachusetts General Hospital), Ryan B. Corcoran(Harvard University), Dora Dias‐Santagata(Center for Cancer Research), Bezaye Teshome(Massachusetts General Hospital), Jaime L. Schneider(Harvard University), Colin D. Weekes(Massachusetts General Hospital), Heather A. Shahzade(Harvard University), Giulia Siravegna(University of Turin), Theodore S. Hong(University of Massachusetts Chan Medical School), Katie Kanter(Massachusetts General Hospital), A. John Iafrate(Apple (Israel)), Madeleine G. Fish(Massachusetts General Hospital), Lipika Goyal(Massachusetts General Hospital), Emily E. Van Seventer(Massachusetts General Hospital), Jochen K. Lennerz(Massachusetts General Hospital), David P. Ryan(Johns Hopkins University), Nora Horick(Massachusetts General Hospital), Jennifer Y. Wo(Harvard University), Kathryn Fosbenner(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Bruce J. Giantonio(Massachusetts General Hospital), Isobel J. Fetter(Harvard University), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Massachusetts General Hospital), Brandon Nadres(Massachusetts General Hospital), Ashraf Thabet(Harvard University), Amikasra Mojtahed(Harvard University), Ryan David Nipp(Harvard University), Jill N. Allen(Harvard University), Eric Roeland(Harvard University)
Cited by 143
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k